Immunologic predictors of HIV-related survival among Texas prison inmates

AIDS Patient Care and STDs

Volumn 14, Issue 4, 2000, Pages 183-187

  Baillargeon, Jacques ^a   Grady, James ^b   Borucki, Michael J ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRISON; PRISONER; PROGNOSIS; SURVIVAL;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PRISONERS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; SURVIVAL RATE; TEXAS;

EID: 0033994896     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729100317786     Document Type: Article

References (17)

1. Anno B. Health behavior in prisons and correctional facilities. In Gochmann, DS (ed.) Handbook of Health Behavioral Research. New York: Plenum, 1997.
2. Dixon P, Flannigan T, DeBuono B. Infection with the human immunodeficiency virus in prisoners: Meeting the health care challenge. Am J Med 1993;95: 629-635.
3. Griffin M, Ryan J, Briscoe V, et al. Effects of incarceration on HIV-infected individuals. J Natl Med Assoc 1996;88,639-644.
4. Hammet T. AIDS in correctional facilities: issues and options. Rockville MD: US Department of Justice, National Institute of Justice. 1986.
5. Harding T. Prison medicine. Lancet 1987;28,1260-1263.
6. Mergenhagen P. The prison population bomb. Am Demograph 1996;18,36-40.
7. Weisfuse I, Greenberg B, Back S. et al. HIV-1 infection among New York City inmates. AIDS 1991;5, 1133-1138.
8. Baillargeon J, Borucki M, Grady J. Immunologic predictors of HIV-related survival. Int J STDs & AIDS 1999;10:467-470.
9. Saah AJ, Hoover DR, He Y, Kingsley LA, Phair JP, et al. Factors influencing survival after AIDS: report from the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 1994;7,287-295.
10. Stein D, Korvick J, Vermud S. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992;165,352-63.
11. Taylor J, Fahey JL, Detels R, Giorgi J. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989;2,114-124.
12. Kamps BS, Brodt R, Strazewski S, Bergmann L, Helm E. AIDS-free survival and overall survival in HIV infection: the new classification system for HIV disease and AIDS. Clin Invest 1994;72:283-287.
13. Chaisson RE, Keruly J, Richman DD, Moore RD. Pneumocystis prophylaxis and survival in patients with AIDS and advanced AIDS related complex. JAMA 1989;262:2405-2410.
14. Moore RD, Keruly J, Richman DD, et al. Natural history of advanced HIV disease in patients treated with zidovudine. AIDS 1992;6:671-677.
15. Allison P. Survival analysis: A self-learning text. New York: Springer, 1995.
16. Mackewicz CE, Ortega HW, Levy JA. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clinic Inves 1995;87:1462-1466.
17. Fiala M, Swartz J, Teklehaimanot S, Kermain V, Funnye A, Sayre J, Gornbein J. Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset. Lymphology 1997; 30:128-136